GlassScriptPhysician profile
Lindsey M Ashley
NPI 1700210473
$1,771.66
in general payments reported to CMS, 2019-2025
28 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $324 · 2023: $463 · 2024: $276 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,242.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $358.30 | 2021-2025 | |
| Pfizer INC. | $209.48 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $152.90 | 2021-2025 | Trintellix |
| Bausch Health US, LLC | $97.10 | 2022-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $83.08 | 2023-2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $76.00 | 2021-2023 | Arexvy |
| Neos Therapeutics, LP | $68.33 | 2022-2025 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $65.65 | 2023-2025 | Xelstrym, Secuado |
| Teva Pharmaceuticals USA, INC. | $62.09 | 2023-2025 | Ajovy, Austedo |
| Novo Nordisk INC | $50.61 | 2022-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $48.60 | 2025 | Breztri |
| Idorsia Pharmaceuticals US INC | $45.48 | 2023 | Quviviq |
| Corium, LLC | $43.58 | 2024-2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $43.13 | 2022-2024 | |
| Viiv Healthcare Company | $42.20 | 2023-2025 | Apretude |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $41.34 | 2024-2025 | |
| Lundbeck LLC | $38.93 | 2023-2025 | Rexulti |
| Dexcom, INC. | $32.29 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.21 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $30.13 | 2021 | |
| Abbott Laboratories | $24.23 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $23.10 | 2022 | |
| Redhill Biopharma INC. | $22.86 | 2021 | |
| Esperion Therapeutics, INC. | $18.20 | 2023 | Nexletol |
| Lilly USA, LLC | $17.50 | 2025 | Zepbound, Mounjaro |
| Ironshore Pharmaceuticals INC. | $17.02 | 2024 | |
| Halozyme INC | $14.41 | 2023 | |
| Paratek Pharmaceuticals, INC. | $13.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Ashley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.